Qianran Hong

Qianran Hong

Auto-generated profile, based on publicly available information

Qianran Hong

The First Affiliated Hospital of Zhejiang Chinese Medical University , (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2024 in Discover Oncology
Verified
Journal Article
Open access
PDF file
SQShengliang Qiu
Shengliang Qiu
WLWeiye Lin
Weiye Lin
ZZZhengyang Zhou
Zhengyang Zhou
QHQianran Hong
Qianran Hong
SCShuangyu Chen
Shuangyu Chen
DCDawei Cui
Dawei Cui
Background Thymocyte selection-associated HMG-BOX (TOX) belongs to a family of transcription factors containing a highly conserved region of the high mobility group box (HMG-Box). A growing body of research has shown that TOX is involved in the occurrence and development of tumors and promotes T-cell exhaustion. We assessed the role of TOX with The Cancer Genome Atlas (TCGA) Pancancer Data. Methods TOX expression was examined with RNA-seq data from the TCGA and Genotype-Tissue Expression (GTEx) databases. The genetic alteration status and protein level of TOX were analyzed using databases, including the Human Protein Atlas (HPA), GeneCards, and STRING. The prognostic significance was estimated with survival data from the TCGA. Moreover, R software was used for enrichment analysis of TOX. The relationship between TOX and immune cell infiltration was assessed with the Tumor Immune Estimation Resource (TIMER) 2.0 database and the “CIBERSORT” method. The correlation between TOX and immune checkpoints was further explored. Immunohistochemical analysis was used to further verify the difference in TOX expression between cancerous and paracancerous tissues, and cell viability was evaluated using a CCK-8 assay. Results In most cancer types in the TCGA cohort, differential TOX expression was observed. The genetic alteration status and protein level of TOX were examined, and the prognosis of cancers was associated with TOX expression. Moreover, TOX levels were closely related to different immune-related pathways, immune cell infiltration and immune checkpoints. Additionally, significant differences in TOX expression between several cancerous and paracancerous tissues were validated. Furthermore, TOX clearly impacted the viability of cancer cells. Conclusions TOX, a potential biomarker for cancer, may be involved in the regulation of the immune microenvironment and can be used for new targeted drugs.

1 May 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
QHQianran Hong
Qianran Hong
WLWeiye Lin
Weiye Lin
YYYici Yan
Yici Yan
SCShuangyu Chen
Shuangyu Chen
JLJiayang Li
Jiayang Li
SQShengliang Qiu
Shengliang Qiu
Purpose: To explore the mechanism of Huashi Jiedu Decoction (HJD) synergizing with 5-fluorouracil (5-Fu) in gastric cancer (GC) therapy. Methods: MicroRNAs (miRNAs) and genes involved in HJD-mediated GC treatment were identified using ultra-high-performance liquid chromatography coupled with quadrupole-Orbitrap mass spectrometry, network pharmacology, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and molecular docking. The effects of HJD on 5-Fu sensitivity in BGC-823 cells were evaluated with 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, reverse transcription quantitative polymerase chain reaction (RT-qPCR), and Western blotting. Synergistic effects in vector-transfected and miRNA-21-3p knockdown cells were assessed by colony formation, wound healing, transwell assays, and flow cytometry (FCM). An in vivo study evaluated the impact of HJD on 5-Fu sensitivity, measuring miRNA-21-3p, tumor protein p53 (p53), N-cadherin, vimentin, and E-cadherin in tumors, along with tumor volume and weight. Results: miRNA-21-3p and p53 were key targets in HJD’s therapeutic effect on GC. RT-qPCR showed that HJD combined with 5-Fu reduced miRNA-21-3p and upregulated p53 in vector cells and increased p53 mRNA (p < 0.01) and protein (p < 0.05) compared to 5-Fu alone. These effects were abolished in miRNA-21-3p knockdown cells. The combination reduced colony formation by 48.92% (p < 0.01), suppressed transwell migration by 28.5% (p < 0.01), and inhibited wound healing by 81.9% compared to 5-Fu monotherapy (p < 0.001), with no effects in knockdown cells. FCM showed a 15.1% increase in G0/G1 phase arrest (p < 0.05). In vivo, the combination significantly reduced tumor volume (p < 0.05) and weight by 18.7%, with concomitant miRNA-21-3p downregulation (p < 0.0001), EMT marker suppression (N-cadherin, vimentin), and tumor suppressor activation (p53, E-cadherin) versus 5-Fu alone. Conclusion: HJD enhances 5-Fu’s effects on GC by regulating the miRNA-21-3p/p53 pathway and modulating cadherin expression, supporting its potential as an adjunctive treatment in GC.



22 May 2024 in Research Square
Verified
Preprint
Open access
PDF file
SQShengliang Qiu
Shengliang Qiu
WLWeiye Lin
Weiye Lin
ZZZhengyang Zhou
Zhengyang Zhou
QHQianran Hong
Qianran Hong
SCShuangyu Chen
Shuangyu Chen
DCDawei Cui
Dawei Cui
Background TOX (Thymocyte Selection-Associated HMG BOX) belongs to a family of transcription factors with a conserved high mobility group box (HMG-box) domain. Research indicates that TOX is involved in tumor development and T cell exhaustion. This study used data from The Cancer Genome Atlas (TCGA) to evaluate TOX expression across cancers. Methods TOX expression was analyzed using RNAseq data from TCGA and the Genotype-Tissue Expression (GTEx) database. Genetic alterations and protein levels were assessed via Human Protein Atlas (HPA), GeneCards, and String databases. Prognostic significance was determined using Kaplan-Meier analysis and univariate Cox regression. Enrichment analysis was performed using the "clusterProfiler" R package. The relationship between TOX and immune cell infiltration was analyzed via TIMER2 and "CIBERSORT." Differences in TOX expression between cancerous and adjacent normal tissues were confirmed using immunohistochemistry. Results TOX expression varied across TCGA cancer types, with high expression in gliomas and lymphoma and low expression in other cancers. Genetic alterations and protein levels correlated with cancer prognosis and were linked to immune pathways, cell infiltration, and checkpoints. Significant differences in TOX expression between cancerous and adjacent normal tissues were confirmed. Conclusions TOX is a promising biomarker for cancer, likely playing a role in regulating the immune microenvironment and providing opportunities for novel targeted therapies.

5 November 2026 in Cardiovascular Toxicology
Verified
Journal Article
Closed access
PDF file
QHQianran Hong
Qianran Hong
YHYi-bo He
Yi-bo He
YFYiwei Feng
Yiwei Feng
CWCi Wang
Ci Wang
DLDongming Lin
Dongming Lin
SHShuwei Huang
Shuwei Huang